8FW6
Human Lactate Dehydrogenase A in Complex with Inhibitor CHK-336
Summary for 8FW6
| Entry DOI | 10.2210/pdb8fw6/pdb |
| Descriptor | L-lactate dehydrogenase A chain, 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE, (2P)-2-{5-(cyclopropylmethyl)-3-(4-fluorophenyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid, ... (6 entities in total) |
| Functional Keywords | ldha hldha human lactate dehydrogenase a, oxidoreductase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 2 |
| Total formula weight | 78680.38 |
| Authors | Lowther, W.T.,Gumpena, R. (deposition date: 2023-01-20, release date: 2024-01-24, Last modification date: 2025-09-17) |
| Primary citation | Cox, J.H.,Boily, M.O.,Caron, A.,Sheng, T.,Wu, J.,Ding, J.,Gaudreault, S.,Chong, O.,Surendradoss, J.,Gomez, R.,Lester, J.,Dumais, V.,Li, X.,Gumpena, R.,Hall, M.D.,Waterson, A.G.,Stott, G.,Flint, A.J.,Moore, W.J.,Lowther, W.T.,Knight, J.,Percival, M.D.,Tong, V.,Oballa, R.,Powell, D.A.,King, A.J. Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment. J Am Soc Nephrol, 36:1535-1547, 2025 Cited by PubMed Abstract: Primary hyperoxalurias are genetic diseases defined by elevated hepatic oxalate production and higher incidence of kidney stones. Lactate dehydrogenase A catalyzes the final and committed step in hepatic oxalate synthesis and represents a potential therapeutic target for primary hyperoxalurias. CHK-336 is a liver-targeted, small-molecule lactate dehydrogenase A inhibitor with potential to treat diseases associated with elevated oxalate production. PubMed: 40193200DOI: 10.1681/ASN.0000000690 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.34 Å) |
Structure validation
Download full validation report
